Shuxuetong (SXT) Injection Active Peptides
Three angiogenic peptides (DSYVGDEAQSKR, YNELRVAPEEHP, IQFLPEGSPVTM) from a leech + earthworm Shuxuetong (SXT) injection — Sun 2022 hindlimb-ischemia model.
Praeklinisch / mechanistischLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Three angiogenic peptides (DSYVGDEAQSKR, YNELRVAPEEHP, IQFLPEGSPVTM) from a leech + earthworm Shuxuetong (SXT) injection — Sun 2022 hindlimb-ischemia model.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Shuxuetong is a registered TCM injection in China; its safety / efficacy outside that regulatory framework is not established. The three active peptides have not been individually tested in randomised human trials. No FDA approval.
Molecular Profile
- Category
- Vasodilator
- Evidence tier
- Preclinical
- Source species
- Hirudo nipponia + Pheretima (earthworm) composite
- Discovered
- 2022 · Sun W et al.
Biological Targets
- → MYPT1 / LIMK1 / Cofilin pathway; VEGF-A / PDGF-BB upregulation
Key Citations
- Sun W et al. (2022), J Ethnopharmacol · PMID 35248678
External Resources
Related Vasodilator Compounds
Leech Nitric Oxide Synthase Modulator
Modulates host NOS activity at bite site — contributes to vasodilation phase of feeding.
Leech Histamine-like Vasodilator
Histamine-receptor-acting compound — contributes to local vasodilation at feeding site.
Leech Acetylcholine
Cholinergic vasodilator contributing to feeding-site vascular dilation.
Leech Bradykinin Modulator
Salivary factor reported to modulate the bradykinin / kinin-kallikrein vasoactive cascade.